Digoxin composition oral liquid and preparation method thereof
By using cyclodextrin and pH regulator in the oral liquid of digoxin composition, the problems of low solubility and poor stability of digoxin in water are solved. Combined with specific preservatives, the drug safety and preparation stability of children's patients are achieved. It avoids ethanol poisoning and microbial contamination, ensures antibacterial efficacy, and is suitable for industrial production.
Patent Information
- Application Number
- CN202411054106.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-22
AI Technical Summary
The existing digoxin preparations have a great risk to childhood patients. Digoxin is unstable and prone to hydrolysis reactions. Preservatives are unstable in some formulation systems, which affects the antibacterial efficacy. Moreover, because digoxin is difficult to dissolve in water, The risk of poisoning is caused by the need to be added to a large amount of ethanol, and the oral liquid is susceptible to microbial contamination.
Provide a digoxin composition oral solution without ethanol or surfactant. By adding cyclodextrin and pH adjuster, the solubility and stability of digoxin in water are improved, and the pH value is adjusted with buffers, combined with specific Types of preservatives, prepare a stable and safe oral liquid to avoid hydrolysis reactions and preservative degradation, and ensure the safety of medication for children.
It significantly improves the safety of digoxin preparations, avoids the risk of ethanol poisoning, ensures the safety of medication for children, ensures the stability and antibacterial efficacy of the preparations, reduces the health hazards caused by microbial contamination, and is suitable for industrial production.
Smart Images

Figure BDA0004975810790000021 
Figure BDA0004975810790000061 
Figure BDA0004975810790000071
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical preparations, and specifically relates to a digoxin composition oral liquid and a preparation method thereof. Background Art
[0002] The chemical name of digoxin is (3β-[[O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy]-12β,14β-dihydroxy-5β-cardiosteroid-20(22)ene lactone. It is a white or nearly white powder or colorless crystals with a melting point of 248- At 250℃, it is almost insoluble in water and ether, slightly soluble in 50% ethanol and chloroform, easily soluble in pyridine, and easily degraded by light. Digoxin is a medium-acting cardiac glycoside drug, which has a positive inotropic effect on the heart, slows the heart rate, and inhibits cardiac conduction. It is suitable for low-output congestive heart failure, atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia. It is used for various acute and chronic heart failures, supraventricular tachycardia, atrial fibrillation and flutter, etc.
[0003] At present, the commercially available dosage forms of digoxin include tablets, powders, oral solutions and oral preparations. Oral absorption is rapid and complete, with a bioavailability of more than 90%. The plasma drug concentration reaches a peak 1 hour after taking the drug, reaches a significant effect after 4 hours, and reaches the maximum effect after 6 to 12 hours. The serum therapeutic concentration is 15 to 25 ng / ml, and the plasma protein binding rate is 97%. It mainly disappears through liver microsomal enzyme metabolism, and the elimination half-life is generally 4 to 7 days. It is excreted by bile, and after recycling, it is excreted by urine. It is usually administered orally. When administered to children, tablets and powders usually have the risk of failing to reach therapeutic concentrations or overdose, which can easily cause acute digoxin poisoning in children. At the same time, tablets and powders have poor compliance in clinical administration of children because they need to swallow the drugs. Therefore, Hikma, an American company, launched digoxin oral solution on August 26, 2004.
[0004] Digoxin oral solution is rapidly and completely absorbed, has high bioavailability, and has good compliance in clinical use. However, the oral solution has the following problems: Since digoxin is difficult to dissolve in water, Hikma's digoxin oral solution adds a large amount of organic solvents to increase the solubility of digoxin, including 10.0% (V / V) ethanol. However, children have a low tolerance to ethanol, with a lethal dose of about 6 to 10g for infants and about 25g for children. Ethanol can also cause adverse reactions such as central nervous system depression and muscle incoordination, and visual impairment in neonates. Other most common alcohol-related toxicities in children include hypoglycemia, acidosis, and electrolyte abnormalities, which are more likely to occur than in adults. The STEP database mentions reports of acute toxicity cases in children at lower blood ethanol concentrations.
[0005] Oral liquids often fail to meet hygiene standards due to microbial contamination, causing huge economic losses. In addition, the microbial reproduction process produces endotoxins and allergens, which can cause secondary diseases after patients take contaminated oral liquids. This directly or indirectly harms humans. In order to prevent drugs from deteriorating due to microbial contamination, manufacturers often add preservatives to inhibit microorganisms in the production of oral liquids in addition to sterilizing raw materials and finished products and improving the production environment. Preservatives commonly used in oral liquids include methylparaben, ethylparaben, propylparaben, butylparaben, benzoic acid, chlorobutanol, potassium sorbate, etc. Preservatives are often affected by the acidity and alkalinity of the liquid, so it is necessary to select appropriate preservatives and determine the preservative content and antibacterial efficacy.
[0006] Preservatives are added to the digoxin oral solution currently on the market, but their content is not controlled in the quality standards. Preservatives are not stable in certain formulation systems and may degrade, thus affecting the quality of the drug.
[0007] In view of the fact that existing digoxin preparations pose a greater risk to pediatric patients, digoxin is unstable and prone to hydrolysis to produce hydrolysis impurity F, and preservatives may also undergo degradation reactions, affecting the antibacterial efficacy, at present, digoxin compositions still need to be further improved.
[0008] Summary of the invention
[0009] The present invention aims to provide an oral digoxin composition liquid without ethanol or surfactant and a preparation method thereof, which can improve the safety of digoxin preparations and is suitable for industrial production. Moreover, the preparations of the present invention can ensure stability during storage.
[0010] In a first aspect of the present invention, a digoxin composition oral liquid is provided, comprising digoxin with m / v concentrations of 1-10 mg / 100 mL, 0.25-5 g / 100 mL of cyclodextrin, 0.05-0.3 g / 100 mL of a pH regulator and 0.05-0.2 g / 100 mL of a preservative.
[0011] The specific prescription of the present invention can well solve the problem of low solubility of digoxin in water, provide a milder aqueous solution, avoid ethanol poisoning caused by using a large amount of ethanol, reduce the risk of preparation poisoning, and ensure the safety of medication for children. In addition, by adding a pH regulator, the stability of digoxin in the water system is achieved and the patient's compliance with use is increased.
[0012] In a preferred embodiment of the present invention, the oral liquid composition comprises digoxin at m / v concentrations of 1-10 mg / 100 mL, 0.5-2 g / 100 mL of cyclodextrin, 0.07-0.2 g / 100 mL of a pH adjuster and 0.05-0.2 g / 100 mL of a preservative.
[0013] In a preferred embodiment of the present invention, the mass ratio of digoxin to cyclodextrin is 1:50 to 1:1000, preferably 1:100 to 1:400.
[0014] In a preferred embodiment of the present invention, in the oral solution of digoxin composition, the cyclodextrin is hydroxypropyl-β-cyclodextrin, hydroxyethyl-β-cyclodextrin, glucosyl-β-cyclodextrin, carboxymethyl-β-cyclodextrin or sulfobutyl-β-cyclodextrin sodium, preferably hydroxypropyl-β-cyclodextrin or sulfobutyl-β-cyclodextrin sodium.
[0015] In a preferred embodiment of the present invention, the pH range of the oral liquid composition is 6.8 to 7.8, preferably 7.0 to 7.6.
[0016] In the second aspect of the present invention, the pH regulator of the digoxin composition oral solution is a buffer.
[0017] In a preferred embodiment of the present invention, the buffer is selected from at least one of sodium citrate-citric acid, disodium hydrogen phosphate-citric acid, sodium tartrate-tartaric acid, lactic acid-sodium lactate, and acetic acid-sodium acetate, preferably sodium citrate-citric acid or disodium hydrogen phosphate-citric acid.
[0018] In a preferred embodiment of the present invention, the pH range of the oral solution of the composition is adjusted by the buffer.
[0019] In a preferred embodiment of the present invention, the pH range of the oral solution of the composition is 6.8 to 7.8, preferably 7.0 to 7.6, after being adjusted by the buffer.
[0020] In a preferred embodiment of the present invention, the preservative is selected from at least one of methylparaben, ethylparaben, propylparaben and butylparaben, preferably propylparaben or butylparaben, or a combination of propylparaben and butylparaben.
[0021] In the third aspect of the present invention, a method for preparing a digoxin oral liquid composition is provided: (1) adding water at room temperature and stirring to dissolve the cyclodextrin, the preservative and the buffer to obtain a cyclodextrin aqueous solution; (2) slowly adding digoxin to the cyclodextrin aqueous solution of step (1) at a certain temperature and a certain stirring speed to obtain a digoxin aqueous solution, adjusting the pH value of the solution, filtering through a 0.22 μm microporous sterile filter membrane, and filling to obtain a pure water-based digoxin oral liquid composition.
[0022] The beneficial effects of the present invention are:
[0023] 1. The safety of the improved oral digoxin composition liquid is significantly improved. The oral digoxin liquid currently sold on the market contains 10% ethanol, which can cause adverse reactions such as central nervous system depression, muscle incoordination, and visual impairment in newborns. The final product of the digoxin composition of the present invention does not contain ethanol, thus avoiding the toxicity problem caused by the use of a large amount of organic solvents, reducing the risk of poisoning in the preparation, and ensuring the safety of medication for children.
[0024] 2. The improved digoxin combination oral liquid formula is stable. Digoxin-cyclodextrin-preservative-buffer forms a stable combination. The hydrolysis reaction of digoxin is inhibited and the preservative will not be degraded. Within a specific pH range, the combination formula is more stable than the reference preparation. DETAILED DESCRIPTION
[0025] The present invention is further described below in conjunction with specific examples. It should be understood that the following description is only the most preferred embodiment of the present invention and should not be considered as limiting the scope of protection of the present invention. On the basis of a full understanding of the present invention, the experimental methods in the following examples that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. Those skilled in the art may make non-essential changes to the technical solution of the present invention, and such changes should be deemed to be included in the scope of protection of the present invention.
[0026] Example 1: Digoxin 0.005g, hydroxypropyl-β-cyclodextrin 0.25g, citric acid 0.012g, disodium hydrogen phosphate 0.1225g, ethylparaben 0.1g, propylparaben 0.02g, add water to 100ml. The pH value of the final product is 7.2. The preparation method is as follows:
[0027] (1) adding water at room temperature and stirring to dissolve the cyclodextrin, the preservative and the buffer to obtain a cyclodextrin aqueous solution; (2) slowly adding digoxin to the cyclodextrin aqueous solution of step (1) at a certain temperature and a certain stirring speed (a speed that can achieve material dissolution) to obtain a digoxin aqueous solution, adjusting the pH value of the solution, filtering through a 0.22 μm microporous sterile filter membrane, and filling to obtain a pure water-based digoxin composition oral solution.
[0028] Example 2: Digoxin 0.005g, hydroxypropyl-β-cyclodextrin 1.0g, disodium hydrogen phosphate 0.147g, citric acid 0.024g, propylparaben 0.1g, butylparaben 0.02g, add water to 100ml. The pH value of the final product is 7.2. The preparation method is the same as that of Example 1.
[0029] Example 3: Digoxin 0.005g, sodium sulfobutyl-β-cyclodextrin 2.0g, disodium hydrogen phosphate 0.178g, citric acid 0.016g, propylparaben 0.1g, butylparaben 0.02g, add water to 100ml. The pH value of the final product is 7.2. The preparation method is the same as that of Example 1.
[0030] Example 4: 0.005 g of digoxin, 1.0 g of sodium sulfobutyl-β-cyclodextrin, 0.009 g of citric acid, 0.124 g of disodium hydrogen phosphate, 0.1 g of propylparaben, 0.02 g of butylparaben, add water to 100 ml. The pH value of the final product is 7.6. The preparation method is the same as that of Example 1.
[0031] Example 5: 0.005 g of digoxin, 1.0 g of hydroxypropyl-β-cyclodextrin, 0.01 g of citric acid, 0.06 g of disodium hydrogen phosphate, 0.1 g of propylparaben, 0.02 g of butylparaben, add water to 100 ml. The pH value of the final product is 7.0. The preparation method is the same as that of Example 1.
[0032] Example 6: 0.005 g of digoxin, 1.0 g of hydroxypropyl-β-cyclodextrin, 0.01 g of citric acid, 0.05 g of disodium hydrogen phosphate, 0.1 g of propylparaben, 0.02 g of butylparaben, add water to 100 ml. The pH value of the final product is 6.8. The preparation method is the same as that of Example 1.
[0033] Example 7: 0.005 g of digoxin, 1.0 g of sodium sulfobutyl-β-cyclodextrin, 0.008 g of citric acid, 0.127 g of disodium hydrogen phosphate, 0.1 g of propylparaben, 0.02 g of butylparaben, add water to 100 ml. The pH value of the final product is 7.8. The preparation method is the same as that of Example 1.
[0034] Example 8: Add water to 100 ml of digoxin 0.005 g, sodium sulfobutyl-β-cyclodextrin 1.0 g, citric acid 0.009 g, disodium hydrogen phosphate 0.124 g, and propylparaben 0.12 g. The pH value of the final product is 7.6. The preparation method is the same as that of Example 1.
[0035] Example 9: Add water to 100 ml of digoxin 0.005 g, hydroxypropyl-β-cyclodextrin 1.0 g, citric acid 0.010 g, disodium hydrogen phosphate 0.060 g, butylparaben 0.12 g. The final product has a pH value of 7.0. The preparation method is the same as that of Example 1.
[0036] Example 10: Digoxin 0.005g, hydroxypropyl-β-cyclodextrin 5.0g, citric acid 0.02g, disodium hydrogen phosphate 0.1225g, propylparaben 0.1g, butylparaben 0.02g, add water to 100ml. The pH value of the final product is 7.2. The preparation method is the same as that of Example 1. Comparative Example 1: Digoxin 0.005g, hydroxypropyl-β-cyclodextrin 0.2g, citric acid 0.02g, disodium hydrogen phosphate 0.1225g, propylparaben 0.1g, butylparaben 0.02g, add water to 100ml. The pH value of the final product is 7.2. The preparation method is the same as that of Example 1. Comparative Example 2: Digoxin 0.005g, hydroxypropyl-β-cyclodextrin 1.0g, citric acid 0.038, disodium hydrogen phosphate 0.1225g, propylparaben 0.1g, butylparaben 0.02g, add water to 100ml. The pH value of the final product is 6.7, and the preparation method is as in Example 1. Comparative Example 3: Digoxin 0.005g, sulfobutyl-β-cyclodextrin sodium 1.0g, citric acid 0.008g, disodium hydrogen phosphate 0.136g, propylparaben 0.1g, butylparaben 0.02g, add water to 100ml. The pH value of the final product is 7.9. The preparation method is the same as in Example 1.
[0037] Example 11: Digoxin 0.005g, hydroxypropyl-β-cyclodextrin 1.0g, citric acid 0.024g, disodium hydrogen phosphate 0.147g, methylparaben 0.1g, ethylparaben 0.02g, add water to 100ml. The pH value of the final product is 7.2. The preparation method is the same as that of Example 1.
[0038] Example 12: Digoxin 0.005g, hydroxypropyl-β-cyclodextrin 1.0g, citric acid 0.017g, disodium hydrogen phosphate 0.147g, methylparaben 0.1g, propylparaben 0.02g, add water to 100ml. The pH value of the final product is 7.4. The preparation method is the same as that of Example 1.
[0039] Example 13: Digoxin 0.005g, hydroxypropyl-β-cyclodextrin 1.0g, citric acid 0.024g, disodium hydrogen phosphate 0.147g, ethylparaben 0.1g, add water to 100ml. The pH value of the final product is 7.2. The preparation method is the same as that of Example 1.
[0040] Example 14: Digoxin 0.005g, hydroxypropyl-β-cyclodextrin 1.0g, citric acid 0.017g, disodium hydrogen phosphate 0.147g, methylparaben 0.1g, add water to 100ml. The pH value of the final product is 7.4. The preparation method is the same as that of Example 1.
[0041] Example 15: Digoxin 0.005g, hydroxypropyl-β-cyclodextrin 1.0g, citric acid 0.024g, disodium hydrogen phosphate 0.125g, ethylparaben 0.1g, propylparaben 0.02g, add water to 100ml. The pH value of the final product is 7.1. The preparation method is the same as that of Example 1.
[0042] Comparative Example 4: 0.005 g of digoxin, 1.0 g of hydroxypropyl-β-cyclodextrin, 0.020 g of citric acid, 0.147 g of disodium hydrogen phosphate, 0.12 g of benzoic acid, add water to 100 ml. The pH value of the final product is 7.3. The preparation method is the same as that of Example 1.
[0043] Comparative Example 5: 0.005 g of digoxin, 1.0 g of hydroxypropyl-β-cyclodextrin, 0.024 g of citric acid, 0.147 g of disodium hydrogen phosphate, 0.15 g of chlorobutanol, add water to 100 ml. The pH value of the final product is 7.2. The preparation method is the same as that of Example 1.
[0044] Comparative Example 6: 0.005 g of digoxin, 1.0 g of hydroxypropyl-β-cyclodextrin, 0.024 g of citric acid, 0.147 g of disodium hydrogen phosphate, 0.11 g of potassium sorbate, add water to 100 ml. The pH value of the final product is 7.2. The preparation method is the same as that of Example 1.
[0045] Test Example 1:
[0046] The above Examples 1-3, 10 and 1 group of comparative examples were investigated for solution properties and related substances. The standard for oral digoxin solution stipulates that the digoxin content is within the range of 90%-110%, the known impurity F is less than 2%, and the total impurity is less than 5%. When the mass ratio of digoxin raw material to cyclodextrin is greater than 1:50, digoxin cannot be completely dissolved. When the mass ratio of digoxin to cyclodextrin is less than or equal to 1:50, digoxin can be dissolved, but as the ratio of cyclodextrin increases, the stability of digoxin injection decreases. When the ratio of digoxin to cyclodextrin is not greater than 1:50 and not less than 1:400, the impurity F is less than 2.0% and the total impurity is less than 5.0 after the sample is placed at a high temperature of 60°C for 10 days. However, when the ratio of digoxin to cyclodextrin is 1:1000, after being placed at high temperature of 60°C for 10 days, impurity F has increased to 1.95%, close to the limit of 2.0%, and total impurities have also increased to 4.97%, close to the limit of 5.0%. Therefore, when the ratio of digoxin to cyclodextrin is less than 1:1000, the relevant substances will be unqualified. Only when the ratio of digoxin to cyclodextrin is within the appropriate range, digoxin has good solubility and stability.
[0047] Table 1 Study on the influence of excipient ratio on stability
[0048]
[0049] Test Example 2:
[0050] The above 2, 4, 5, 6, 7 groups of embodiments and 2-3 groups of comparative embodiments were investigated for content and related substances. The standard for oral digoxin solution stipulates that the digoxin content is in the range of 90%-110%, the known impurity F is less than 2%, and the total impurities are less than 5%. When the pH value of the liquid medicine is in the range of 7.0-7.6, the impurity F and the total impurities are small, and the impurities F and the total impurities are within the standard limits after being placed at high temperature for 10 days. When the pH value of the liquid medicine is 6.8 or 7.8, the content is slightly reduced, the impurity F and the total impurities are slightly increased, but the product is qualified. When the pH value of the liquid medicine is less than 6.8 or the pH value is greater than 7.8, the digoxin content is significantly reduced, the impurity F and the total impurities are significantly increased, and the impurity F and the total impurities are both beyond the limit after being placed at high temperature for 10 days.
[0051] After many studies, the present invention unexpectedly found that the pH value of the drug solution would affect the hydrolysis reaction of digoxin. + or OH - The digoxin-cyclodextrin composition of the present invention can inhibit the hydrolysis of digoxin only in the pH range of 6.8 to 7.8, and the sample is stable.
[0052] Table 2 Study on the effect of pH on stability
[0053]
[0054] Test Example 3:
[0055] Antibacterial efficacy tests and preservative content experiments were conducted on Examples 2, 8, 9, 11-15 and Comparative Examples 4-6, and a reference preparation of digoxin oral solution that has been on the market was purchased for comparative study. The standard for digoxin oral solution stipulates that the preservative content is in the range of 90%-110%. Antibacterial efficacy test method: According to the 2020 edition of the Chinese Pharmacopoeia, Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans and Aspergillus niger were used as test strains to conduct a colony counting method applicability test. According to the test results, a sample microbial challenge test was carried out, and the lg value of the number of surviving test bacteria in the sample at different times was determined, and compared with the initial inoculation lg value to judge the antibacterial efficacy. According to the antibacterial efficacy results of the antibacterial agent, a concentration gradient was designed, and the most suitable type of antibacterial agent was investigated. The criteria for judging the antibacterial efficacy of oral solution are as follows:
[0056] Table 3 Judgment criteria for antibacterial efficacy of oral solution
[0057]
[0058]
[0059] Most oral liquid preservatives will degrade when pH is above 7.0, and the preservative content will decrease, thus affecting the antibacterial effect, so the preservative content in the oral liquid is investigated. The present invention unexpectedly found that the cyclodextrin in the present composition can improve the stability of certain preservatives, so that they will not degrade in a high pH environment and continue to maintain the antibacterial effect. Specifically, the preservative content of Examples 2, 8, and 9 did not decrease after being placed at 60°C for 10 days, while the preservative content of the reference preparation decreased by about 4% after being placed at 60°C for 10 days, and the content of the remaining hydroxyphenyl ester combination samples decreased by about 5% after being placed at 60°C for 10 days, but it was still within the qualified range. The content of preservative samples such as benzoic acid / sorbic acid / trichlorobutanol decreased by more than 10% after being placed at 60°C for 10 days.
[0060] The antibacterial efficacy of paraben preservatives in the range of pH 6.8 to 7.8, especially in the range of pH 7.0 to 7.6, is higher than that of other preservatives. The most effective and stable preservative is ethylparaben or propylparaben, or a combination of propylparaben and butylparaben.
[0061] Table 4 Preservative content of oral solution
[0062]
[0063]
[0064] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A digoxin composition oral liquid, characterized in that: The oral liquid composition comprises digoxin with m / v concentrations of 1-10 mg / 100 mL, cyclodextrin of 0.25-5 g / 100 mL, pH regulator of 0.05-0.3 mg / 100 mL and preservative of 0.05-0.2 g / 100 mL.
2. The digoxin composition oral liquid according to claim 1, characterized in that: The oral liquid composition comprises digoxin with m / v concentrations of 1-10 mg / 100 mL, cyclodextrin of 0.5-2 g / 100 mL, pH regulator of 0.07-0.2 g / 100 mL and preservative of 0.05-0.2 g / 100 mL.
3. The digoxin composition oral liquid according to claim 1, characterized in that: The mass ratio of digoxin to cyclodextrin is 1:50 to 1:1000, preferably 1:100 to 1:
400.
4. The cyclodextrin according to claim 1, characterized in that In the digoxin oral liquid composition, the cyclodextrin is hydroxypropyl-β-cyclodextrin, hydroxyethyl-β-cyclodextrin, glucosyl-β-cyclodextrin, carboxymethyl-β-cyclodextrin or sulfobutyl-β-cyclodextrin sodium, preferably hydroxypropyl-β-cyclodextrin or sulfobutyl-β-cyclodextrin sodium.
5. The digoxin composition oral liquid according to claim 1, characterized in that: The pH range of the oral liquid of the composition is 6.8 to 7.8, preferably 7.0 to 7.
6.
6. The digoxin oral liquid composition according to claim 1, characterized in that: The pH regulator of the digoxin composition oral solution is a buffer; Optionally, the buffer is selected from at least one of sodium citrate-citric acid, disodium hydrogen phosphate-citric acid, sodium tartrate-tartaric acid, lactic acid-sodium lactate and acetic acid-sodium acetate, preferably sodium citrate-citric acid or disodium hydrogen phosphate-citric acid; Optionally, the pH range of the oral liquid of the composition is adjusted by the buffer; preferably, the pH range of the oral liquid of the composition is 6.8 to 7.8, preferably 7.0 to 7.6 after being adjusted by the buffer.
7. The digoxin oral liquid composition according to claim 1, characterized in that: The preservative is selected from at least one of methylparaben, ethylparaben, propylparaben and butylparaben, preferably propylparaben or butylparaben, or a combination of propylparaben and butylparaben.
8. A method for preparing the digoxin composition oral solution as claimed in claim 6, characterized in that: (1) adding water at room temperature and stirring to dissolve the cyclodextrin, the preservative and the buffer to obtain a cyclodextrin aqueous solution; (2) at a certain temperature and a certain stirring speed, slowly adding the digoxin to the cyclodextrin aqueous solution of step (1) to obtain a digoxin aqueous solution, adjusting the pH value of the solution, filtering through a 0.22 μm microporous sterile filter membrane, and filling to obtain a pure water-based digoxin composition oral solution.
